Human LPAP (lymphocyte phosphatase associated phosphoprotein) and its mouse homologue, CD45-AP (CD45 associated protein) or LSM-1, represent 32- and 30-kDa transmembrane phosphoproteins that noncovalently associate with the tyrosine phosphatase CD45, a key molecule involved in T- and B-lymphocyte activation. Here we report the isolation and sequencing of genomic clones of the human and mouse genes. LPAP (HGMW-approved symbol PTPRCAP) maps to human chromosome 11q13, distal to the BCL-1 breakpoint, and mouse CD45-AP/LSM-1 maps to Chromosome 19B. Both genes span 3 kb and consist of two exons that are separated by a 1.2-kb intron. The promoter regions do not contain TATA boxes, but possess consensus transcriptional initiator sequences that have also been described for other TATA-less genes. The genomic sequences also provide a genetic basis for two different cDNAs (termed CD45-AP and LSM-1, respectively) that have been described in the mouse system.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1006/geno.1996.0595 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lymphocyte Phosphatase-Associated Phosphoprotein (LPAP) as a CD45 Protein Stability Regulator.
Biochemistry (Mosc)
May 2024
National Research Center Institute of Immunology, Federal Medical Biological Agency of Russia, Moscow, 115522, Russia.
Lymphocyte phosphatase-associated phosphoprotein (LPAP) is a binding partner of the phosphatase CD45, but its function remains poorly understood. Its close interaction with CD45 suggests that LPAP may potentially regulate CD45, but direct biochemical evidence for this has not yet been obtained. We found that in the Jurkat lymphoid cells the levels of LPAP and CD45 proteins are interrelated and well correlated with each other.
View Article and Find Full Text PDFIntroduction of the L-PAP Flap: Bipedicled, Conjoined, and Stacked Thigh-Based Flaps for Autologous Breast Reconstruction.
Plast Reconstr Surg
September 2024
Department of Plastic, Aesthetic, and Reconstructive Surgery, Hospital of the Brothers of St. John of Gods, Paracelsus Medical University, Salzburg, Austria.
Introduction of the L-PAP Flap: Bipedicled, Conjoined, and Stacked Thigh-Based Flaps for Autologous Breast Reconstruction.
Plast Reconstr Surg
December 2023
From the Department of Plastic Surgery, University of Texas MD Anderson Cancer Centers.
Summary: Thigh-based flaps are increasingly popular options for autologous breast reconstruction in the setting of abdominal donor-site inadequacy, previous surgery, or patient preference, but the volume and skin associated with these flaps are often lacking relative to the abdomen. An individualized, shared decision-making approach to donor-site selection was adopted based on body shape, surgical history, lifestyle, reconstructive needs, and patient expectations. Different thigh-based flaps combined in stacked, bipedicled, or conjoined configurations were selected to maximize efficient use of available soft-tissue skin and volume while optimizing donor-site aesthetics.
View Article and Find Full Text PDFQuantifying the contribution of lipoprotein(a) to all apoB containing particles.
J Clin Lipidol
April 2022
Ciccarone Center for the Prevention of Cardiovascular Disease, Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; Welch Center for Prevention, Epidemiology, and Clinical Research, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. Electronic address:
Background: Elevated lipoprotein (a) [Lp(a)] is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD). As clinical LDL cholesterol [LDL-C] incorporates cholesterol from Lp(a) [Lp(a)-C], there is interest in quantifying the contribution of Lp(a)-C to LDL-C given implications for risk assessment, diagnosis, and treatment. Estimating Lp(a)-C is subject to inaccuracies; measuring Lp(a) particle number [Lp(a)-P] is more accurate.
View Article and Find Full Text PDFTofacitinib in Patients Hospitalized with Covid-19 Pneumonia.
N Engl J Med
July 2021
From the Hospital Israelita Albert Einstein (P.O.G., R.H.F., D.D.F.M., B.S.S., S.R.L.A., R.V.P.S., L.P.A.P., K.C., R.G.R.A.P.M., F.M., H.P.G., L.V.R., O.B.), the Heart Institute, InCor, University of São Paulo Medical School (R.H.F., R.K.F., V.M.J.), BP Mirante-A Beneficência Portuguesa de São Paulo (A.M.S.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), and Pfizer (M.D., M.R.T.P.), São Paulo, Centro Integrado de Pesquisa, Hospital de Base, São José do Rio Preto Medical School, São José do Rio Preto (L.N.M.), Pontifícia Universidade Católica de Campinas, Campinas (J.F.S.), Hospital Universitário São Francisco de Assis na Providência de Deus and Irmandade do Senhor Bom Jesus dos Passos da Santa Casa de Misericórida de Bragança Paulista, Bragança Paulista (M.O.A.), Hospital São Vicente de Paulo, Passo Fundo (A.P.T.), and Hospital Estadual Jayme dos Santos Neves, Vila Velha (P.A.M.) - all in Brazil; Pfizer, Collegeville, PA (D.Q.); Pfizer, Lima, Peru (D.P.L.); Pfizer, Istanbul, Turkey (L.M.G.); Pfizer, Rotterdam, the Netherlands (J.J.D.); and Pfizer, New York (T.K.).
Background: The efficacy and safety of tofacitinib, a Janus kinase inhibitor, in patients who are hospitalized with coronavirus disease 2019 (Covid-19) pneumonia are unclear.
Methods: We randomly assigned, in a 1:1 ratio, hospitalized adults with Covid-19 pneumonia to receive either tofacitinib at a dose of 10 mg or placebo twice daily for up to 14 days or until hospital discharge. The primary outcome was the occurrence of death or respiratory failure through day 28 as assessed with the use of an eight-level ordinal scale (with scores ranging from 1 to 8 and higher scores indicating a worse condition).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!